Human TNF cytokine neutralization with a vNAR from<i>Heterodontus francisci</i>shark: A potential therapeutic use

Camacho-Villegas, Tanya A.; Mata-Gonzalez, Teresa; Paniagua-Solis, Jorge; Sánchez‐Castrejón, Edna; Licea-Navarro, Alexei F.

doi:10.4161/mabs.22593

Cited by 40 publications

(32 citation statements)

References 18 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The shark IgNAR platform can recognize epitopes that the immune systems of mammals cannot, thereby offering opportunities to isolate novel binders and novel cryptic epitopes, potentially with high affinities, that could not otherwise be produced. This characteristic of IgNAR make it a good candidate for therapeutic applications, particularly for viruses where broadly neutralizing humoral immunity is desired but difficult to achieve [75]. …”

Section: Cartilaginous Fish Ighmentioning

confidence: 99%

Fish Immunoglobulins

Mashoof

Criscitiello

2016

Biology

165

116

View full text Add to dashboard Cite

The B cell receptor and secreted antibody are at the nexus of humoral adaptive immunity. In this review, we summarize what is known of the immunoglobulin genes of jawed cartilaginous and bony fishes. We focus on what has been learned from genomic or cDNA sequence data, but where appropriate draw upon protein, immunization, affinity and structural studies. Work from major aquatic model organisms and less studied comparative species are both included to define what is the rule for an immunoglobulin isotype or taxonomic group and what exemplifies an exception.

show abstract

Section: Cartilaginous Fish Ighmentioning

confidence: 99%

Fish Immunoglobulins

Mashoof

Criscitiello

2016

Biology

165

116

View full text Add to dashboard Cite

show abstract

“…97 In addition, several other nanobody-derived therapeutics are already in the pipeline. For instances, anti-IL6R and anti-tumor necrosis factor α nanobodies were developed to treat rheumatoid arthritis, [98][99][100] and an anti-RANKL nanobody was generated for bone loss disorder therapy.…”

Section: Nanobodies As Targeting Therapeuticsmentioning

confidence: 99%

Nanobody-derived nanobiotechnology tool kits for diverse biomedical and biotechnology applications

Wang

Fan

Shao

et al. 2016

IJN

122

107

View full text Add to dashboard Cite

Owing to peculiar properties of nanobody, including nanoscale size, robust structure, stable and soluble behaviors in aqueous solution, reversible refolding, high affinity and specificity for only one cognate target, superior cryptic cleft accessibility, and deep tissue penetration, as well as a sustainable source, it has been an ideal research tool for the development of sophisticated nanobiotechnologies. Currently, the nanobody has been evolved into versatile research and application tool kits for diverse biomedical and biotechnology applications. Various nanobody-derived formats, including the nanobody itself, the radionuclide or fluorescent-labeled nanobodies, nanobody homo- or heteromultimers, nanobody-coated nanoparticles, and nanobody-displayed bacteriophages, have been successfully demonstrated as powerful nanobiotechnological tool kits for basic biomedical research, targeting drug delivery and therapy, disease diagnosis, bioimaging, and agricultural and plant protection. These applications indicate a special advantage of these nanobody-derived technologies, already surpassing the “me-too” products of other equivalent binders, such as the full-length antibodies, single-chain variable fragments, antigen-binding fragments, targeting peptides, and DNA-based aptamers. In this review, we summarize the current state of the art in nanobody research, focusing on the nanobody structural features, nanobody production approach, nanobody-derived nanobiotechnology tool kits, and the potentially diverse applications in biomedicine and biotechnology. The future trends, challenges, and limitations of the nanobody-derived nanobiotechnology tool kits are also discussed.

show abstract

“…The significance of this work was not only to develop a new animal model for IgNAR generation but evolutionarily implied the existence of IgNAR prior to the point of divergence of sharks and the batoids (rays and skates) approximately 220 million years ago; supporting the idea that IgNAR existed in an earlier ancestral organism now continued through the Elasmobranch lineage. To date, the greatest understanding of the IgNAR immune response has emanated from studies conducted in nurse shark but immunization of horn shark has also yielded IgNAR target specific responses [20,33].…”

Section: To Be or Not To Be An Antibodymentioning

confidence: 99%

“…The majority of the earliest antigen-specific VNAR domains came from semi or fully synthetic libraries and were typically used as simple reagent molecules, designed to detect and identify target rather than as possible treatments for disease [25,26,29,30,33,51,52,71,72]. More recently, with the development of better platforms for VNAR isolation, including immunization, the potential for these domains in a therapeutic setting was considered for the first time.…”

Section: Other Reported Vnar Domainsmentioning

confidence: 99%

See 1 more Smart Citation

VNARs: An Ancient and Unique Repertoire of Molecules That Deliver Small, Soluble, Stable and High Affinity Binders of Proteins

Barelle¹,

Porter²

2015

Antibodies

View full text Add to dashboard Cite

At 420 million years, the variable domain of New Antigen Receptors or VNARs are undoubtedly the oldest (and smallest) antigen binding single domains identified in the vertebrate kingdom. Their role as an integral part of the adaptive immune system of sharks has been well established and has served to provide a greater understanding of the evolution of humoral immunity; their cellular components and processes as well as the underlying genetic organization and molecular control mechanisms. Intriguingly, unlike the variable domain of the camelid heavy chain antibodies or VHH, VNARs do not conform to all of the characteristic properties of classical antibodies with an ancestral origin that clearly distinguishes them from true immunoglobulin antibodies. However, this uniqueness of their origin only adds to their potential as next generation therapeutic biologics with their structural and functional attributes and commercial freedom all enhancing their profile and current success. In fact their small size, remarkable stability, molecular flexibility and solubility, together with their high affinity and selectivity for target, all reinforce the potential of these domains as drug candidates. The purpose of this review is to provide an overview of the existing basic biology of these unique domains, to highlight the drug-like properties of VNARs and describe current progress in their journey towards the clinic.

show abstract

Human TNF cytokine neutralization with a vNAR fromHeterodontus franciscishark: A potential therapeutic use

Abstract: (2013) Human TNF cytokine neutralization with a vNAR from Heterodontus francisci shark: A potential therapeutic use, mAbs, 5:1, 80-85,

Cited by 40 publications

References 18 publications

Fish Immunoglobulins

Fish Immunoglobulins

Nanobody-derived nanobiotechnology tool kits for diverse biomedical and biotechnology applications

VNARs: An Ancient and Unique Repertoire of Molecules That Deliver Small, Soluble, Stable and High Affinity Binders of Proteins

Contact Info

Product

Resources

About